These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36320324)

  • 21. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.
    Ousterout DG; Perez-Pinera P; Thakore PI; Kabadi AM; Brown MT; Qin X; Fedrigo O; Mouly V; Tremblay JP; Gersbach CA
    Mol Ther; 2013 Sep; 21(9):1718-26. PubMed ID: 23732986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional correction of dystrophin actin binding domain mutations by genome editing.
    Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR/Cas9-Mediated Genome Editing Corrects Dystrophin Mutation in Skeletal Muscle Stem Cells in a Mouse Model of Muscle Dystrophy.
    Zhu P; Wu F; Mosenson J; Zhang H; He TC; Wu WS
    Mol Ther Nucleic Acids; 2017 Jun; 7():31-41. PubMed ID: 28624206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening.
    Soblechero-Martín P; Albiasu-Arteta E; Anton-Martinez A; de la Puente-Ovejero L; Garcia-Jimenez I; González-Iglesias G; Larrañaga-Aiestaran I; López-Martínez A; Poyatos-García J; Ruiz-Del-Yerro E; Gonzalez F; Arechavala-Gomeza V
    Sci Rep; 2021 Sep; 11(1):18188. PubMed ID: 34521928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-Dependent Echocardiographic and Pathologic Findings in a Rat Model with Duchenne Muscular Dystrophy Generated by CRISPR/Cas9 Genome Editing.
    Sugihara H; Kimura K; Yamanouchi K; Teramoto N; Okano T; Daimon M; Morita H; Takenaka K; Shiga T; Tanihata J; Aoki Y; Inoue-Nagamura T; Yotsuyanagi H; Komuro I
    Int Heart J; 2020 Nov; 61(6):1279-1284. PubMed ID: 33191355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of viral vectors as vehicles for DMD gene editing.
    Maggio I; Chen X; Gonçalves MA
    Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward the correction of muscular dystrophy by gene editing.
    Olson EN
    Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34074727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strand bias in oligonucleotide-mediated dystrophin gene editing.
    Bertoni C; Morris GE; Rando TA
    Hum Mol Genet; 2005 Jan; 14(2):221-33. PubMed ID: 15563511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
    Nik-Ahd F; Bertoni C
    Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors.
    Jin Y; Shen Y; Su X; Weintraub N; Tang Y
    J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome Editing Gene Therapy for Duchenne Muscular Dystrophy.
    Hotta A
    J Neuromuscul Dis; 2015 Sep; 2(4):343-355. PubMed ID: 27858753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9.
    Li HL; Fujimoto N; Sasakawa N; Shirai S; Ohkame T; Sakuma T; Tanaka M; Amano N; Watanabe A; Sakurai H; Yamamoto T; Yamanaka S; Hotta A
    Stem Cell Reports; 2015 Jan; 4(1):143-154. PubMed ID: 25434822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common therapeutic advances for Duchenne muscular dystrophy (DMD).
    Salmaninejad A; Jafari Abarghan Y; Bozorg Qomi S; Bayat H; Yousefi M; Azhdari S; Talebi S; Mojarrad M
    Int J Neurosci; 2021 Apr; 131(4):370-389. PubMed ID: 32241218
    [No Abstract]   [Full Text] [Related]  

  • 38. Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy.
    Gee P; Xu H; Hotta A
    Stem Cells Int; 2017; 2017():8765154. PubMed ID: 28607562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.